Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 13/2022

16-08-2022 | Metastasis | Hepatobiliary Tumors

Clinical Usefulness of Postoperative Serum Carcinoembryonic Antigen in Patients with Colorectal Cancer with Liver Metastases

Authors: Koichiro Yoshino, MD, Hiroki Osumi, MD, PhD, Hiromichi Ito, MD, PhD, Daisaku Kamiimabeppu, MD, Akira Ooki, MD, PhD, Takeru Wakatsuki, MD, PhD, Keitaro Shimozaki, MD, Izuma Nakayama, MD, PhD, Mariko Ogura, MD, Daisuke Takahari, MD, PhD, Keisho Chin, MD, Atsushi Oba, MD, PhD, Yoshihiro Ono, MD, PhD, Takafumi Sato, MD, PhD, Yosuke Inoue, MD, PhD, Yu Takahashi, MD, PhD, Kensei Yamaguchi, MD, Eiji Shinozaki, MD, PhD

Published in: Annals of Surgical Oncology | Issue 13/2022

Login to get access

Abstract

Background

Colorectal cancer with liver metastasis (CLM) has high postoperative recurrence rates; therefore, optimizing perioperative treatment is imperative. Postoperative carcinoembryonic antigen (CEA) can aid in detecting minimal residual disease in colon cancer following curative resection. This study aimed to identify the potential role of serum CEA following liver resection in patients with CLM.

Methods

This retrospective study was conducted at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research from 2004 to 2018 and enrolled patients with CLM who underwent complete resection of primary tumors and CLM. Associations between perioperative CEA levels and characteristics of recurrence were investigated.

Results

Recurrence was detected during a median follow-up period of 90.1 months in 343 (54.2%) out of 633 analyzed patients. Patients in the postoperative CEA level > 5 ng/ml group had a significantly higher recurrence rate (75.7% versus 50.0%, p < 0.01) and shorter time until recurrence (4.4 versus 36.9 months, p < 0.01) than those in the postoperative CEA level ≤ 5 ng/ml group. Multivariate analysis revealed that postoperative CEA level > 5 ng/ml was an independent predictor, with hazard ratios of 2.77 (p < 0.01) for recurrence-free survival (RFS) and 3.18 (p < 0.01) for overall survival (OS). Additionally, RFS was significantly shorter among patients in the postoperative CEA level > 5 ng/ml group who did not have normalized CEA levels following adjuvant chemotherapy than among those in the normalized CEA group.

Conclusions

The postoperative and post-adjuvant chemotherapy CEA levels in the CEA level > 5 ng/ml group may be predictors of RFS and OS.
Appendix
Available only for authorised users
Literature
1.
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRefPubMed
2.
3.
Golan T, Urban D, Berger R, Lawrence YR. Changing prognosis of metastatic colorectal adenocarcinoma: differential improvement by age and tumor location. Cancer. 2013;119:3084–91.CrossRefPubMed
4.
Sugihara K. Liver resection for colorectal metastases. Jpn J Gastroenterol Surg. 2000;33:128–33.CrossRef
5.
Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004; 239: 818–825; discussion 25–27.
6.
Martin LW, Warren RS. Current management of colorectal liver metastases. Surg Oncol Clin N Am. 2000; 9: 853-876; discussion 77–78.
7.
Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14:1208–15.CrossRefPubMed
8.
Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol. 1997;15:938–46.CrossRefPubMed
9.
Gayowski TJ, Iwatsuki S, Madariaga JR, et al. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery. 1994; 116: 703-710; discussion 10–11.
10.
Sugihara K, Hojo K, Moriya Y, et al. Pattern of recurrence after hepatic resection for colorectal metastases. Br J Surg. 1993;80:1032–5.CrossRefPubMed
11.
Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med. 1965;121:439–62.CrossRefPubMedPubMedCentral
12.
Hashiguchi Y, Muro K, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25:1–42.CrossRefPubMed
13.
Yoshino T, Arnold D, Taniguchi H, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS SSO and TOS. Ann Oncol. 2018;29:44–70.CrossRefPubMed
14.
Thirunavukarasu P, Talati C, Munjal S, et al. Effect of incorporation of pretreatment serum carcinoembryonic antigen levels into AJCC staging for colon cancer on 5-year survival. JAMA Surg. 2015;150:747–55.CrossRefPubMed
15.
Baqar AR, Wilkins S, Staples M, et al. The role of preoperative CEA in the management of colorectal cancer: a cohort study from two cancer centres. Int J Surg. 2019;64:10–5.CrossRefPubMed
16.
Konishi T, Shimada Y, Hsu M, et al. Association of preoperative and postoperative serum carcinoembryonic antigen and colon cancer outcome. JAMA Oncol. 2018;4:309–15.CrossRefPubMed
17.
Okazaki S, Baba H, Iwata N, Yamauchi S, Sugihara K. Carcinoembryonic antigen testing after curative liver resection for synchronous liver metastasis of colorectal cancer: a Japanese multicenter analysis. Surg Today. 2017;47:1223–9.CrossRefPubMed
18.
Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRefPubMed
19.
Auclin E, André T, Taieb J, et al. Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the Mosaic trial. Br J Cancer. 2019;121:312–7.CrossRefPubMedPubMedCentral
20.
Auclin E, Taieb J, Lepage C, et al. Carcinoembryonic antigen levels and survival in stage III colon cancer: post hoc analysis of the Mosaic and PETACC-8 trials. Cancer Epidemiol Biomarkers Prev. 2019;28:1153–61.CrossRefPubMed
21.
Kato T, Yasui K, Hirai T, et al. Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum. 2003;46:S22-31.PubMed
22.
Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer. 1996;77:1254–62.CrossRefPubMed
23.
Wei AC, Greig PD, Grant D, et al. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol. 2006;13:668–76.CrossRefPubMed
24.
Rees M, Tekkis PP, Welsh FK, O’Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247:125–35.CrossRefPubMed
25.
Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999; 230: 309–318; discussion 18–21.
26.
Figueras J, Torras J, Valls C, et al. Surgical resection of colorectal liver metastases in patients with expanded indications: a single-center experience with 501 patients. Dis Colon Rectum. 2007;50:478–88.CrossRefPubMed
27.
Martin EW Jr, James KK, Hurtubise PE, Catalano P, Minton JP. The use of CEA as an early indicator for gastrointestinal tumor recurrence and second-look procedures. Cancer. 1977;39:440–6.CrossRefPubMed
28.
Wolmark N, Fisher B, Rockette H, et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst. 1988;80:30–6.CrossRefPubMed
29.
Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol. 1999;17:3553–9.CrossRefPubMed
30.
André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–51.CrossRefPubMed
31.
Mitry E, Fields AL, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol. 2008;26:4906–11.CrossRefPubMed
32.
Kanemitsu Y, Kato T, Shimizu Y, et al. A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone as treatment for liver metastasis from colorectal cancer: Japan Clinical Oncology Group Study JCOG0603. Jpn J Clin Oncol. 2009;39(6):406–9.CrossRefPubMed
33.
Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14:531–48.CrossRefPubMed
34.
Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17:223–38.CrossRefPubMed
Metadata
Title
Clinical Usefulness of Postoperative Serum Carcinoembryonic Antigen in Patients with Colorectal Cancer with Liver Metastases
Authors
Koichiro Yoshino, MD
Hiroki Osumi, MD, PhD
Hiromichi Ito, MD, PhD
Daisaku Kamiimabeppu, MD
Akira Ooki, MD, PhD
Takeru Wakatsuki, MD, PhD
Keitaro Shimozaki, MD
Izuma Nakayama, MD, PhD
Mariko Ogura, MD
Daisuke Takahari, MD, PhD
Keisho Chin, MD
Atsushi Oba, MD, PhD
Yoshihiro Ono, MD, PhD
Takafumi Sato, MD, PhD
Yosuke Inoue, MD, PhD
Yu Takahashi, MD, PhD
Kensei Yamaguchi, MD
Eiji Shinozaki, MD, PhD
Publication date
16-08-2022
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 13/2022
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-022-12301-w

Other articles of this Issue 13/2022

Annals of Surgical Oncology 13/2022 Go to the issue

ASO Author Reflections

ASO Author Reflections: The Robotic Versus Laparoscopic Approach to Left and Extended Left Hepatectomy

ASO Author Reflections

ASO Author Reflections: Significance of Loss of Skeletal Muscle Mass During Neoadjuvant Chemotherapy in Older Patients with Esophageal Cancer

Thoracic Oncology

Radiomics to the Rescue

Gastrointestinal Oncology

Indications for Adjuvant Chemotherapy in Stage II Gastric Cancer After D2 Gastrectomy–A Chinese Multicenter Study

ASO Visual Abstract

ASO Visual Abstract: Racial Disparities in Surgical Outcomes Among Women with Endometrial Cancer

Thoracic Oncology

Long-Term Survival After Transhiatal Versus Transthoracic Esophagectomy: A Population-Based Nationwide Study in Finland